Publication: Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control
| dc.contributor.author | Masip, Jenifer | |
| dc.contributor.author | Rallón, Norma | |
| dc.contributor.author | Yeregui, Elena | |
| dc.contributor.author | Olona, Montserrat | |
| dc.contributor.author | Resino, Salvador | |
| dc.contributor.author | Benito, José Miguel | |
| dc.contributor.author | Viladés, Consuelo | |
| dc.contributor.author | García-Pardo, Graciano | |
| dc.contributor.author | Alcamí, José | |
| dc.contributor.author | Ruiz-Mateos, Ezequiel | |
| dc.contributor.author | Gómez-Bertomeu, Frederic | |
| dc.contributor.author | Vargas, Montserrat | |
| dc.contributor.author | Navarro, Marta | |
| dc.contributor.author | Oteo, José A | |
| dc.contributor.author | Pineda, Juan A | |
| dc.contributor.author | Martí, Anna | |
| dc.contributor.author | Alba, Verónica | |
| dc.contributor.author | Vidal, Francesc | |
| dc.contributor.author | Peraire, Joaquin | |
| dc.contributor.author | Rull, Anna | |
| dc.contributor.author | ECRIS integrated in the Spanish AIDS Research Network | |
| dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
| dc.contributor.funder | Red de Investigación Cooperativa en Investigación en Sida (España) | es_ES |
| dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas) | |
| dc.contributor.funder | Rovira i Virgili University (España) | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.contributor.funder | Consejo Superior de Investigaciones Científicas (España) | |
| dc.contributor.funder | Unión Europea. Fondo Social Europeo (ESF/FSE) | |
| dc.contributor.funder | Agència de Gestió d´Ajuts Universitaris i de Recerca (AGAUR) | |
| dc.contributor.funder | Gilead Sciences (Spain) | |
| dc.date.accessioned | 2022-08-05T11:49:47Z | |
| dc.date.available | 2022-08-05T11:49:47Z | |
| dc.date.issued | 2022-04-20 | |
| dc.description.abstract | Long-term elite controllers (LTECs) are a fascinating small subset of HIV individuals with viral and immunological HIV control in the long term that have been designated as models of an HIV functional cure. However, data on the LTEC phenotype are still scarce, and hence, the metabolomics and lipidomics signatures in the LTEC-extreme phenotype, LTECs with more than 10 years of viral and immunological HIV control, could be pivotal to finding the keys for functional HIV remission. Metabolomics and lipidomics analyses were performed using high-resolution mass spectrometry (ultra-high-performance liquid chromatography-electrospray ionization-quadrupole time of flight [UHPLC-(ESI) qTOF] in plasma samples of 13 patients defined as LTEC-extreme, a group of 20 LTECs that lost viral and/or immunological control during the follow-up study (LTEC-losing) and 9 EC patients with short-term viral and immunological control (less than 5 years; no-LTEC patients). Long-term viral and immunological HIV-1 control was found to be strongly associated with elevated tricarboxylic acid (TCA) cycle function. Interestingly, of the nine metabolites identified in the TCA cycle, α-ketoglutaric acid (p = 0.004), a metabolite implicated in the activation of the mTOR complex, a modulator of HIV latency and regulator of several biological processes, was found to be a key metabolite in the persistent control. On the other hand, a lipidomics panel combining 45 lipid species showed an optimal percentage of separation and an ability to differentiate LTEC-extreme from LTEC-losing, revealing that an elevated lipidomics plasma profile could be a predictive factor for the reignition of viral replication in LTEC individuals. | es_ES |
| dc.description.peerreviewed | Sí | es_ES |
| dc.description.sponsorship | This work was supported by the Fondo de Investigación Sanitaria [PI13/0796, PI16/00503, PI16/0684, PI18/1532, PI19/00004, PI19/01127, PI19/01337 PI16/001769, PI19/00973, and PI20/00326]-ISCIII-FEDER (co-funded by the European Regional Development Fund/European Social Fund; “A way to make Europe”/”Investing in your future”); Programa de Suport als Grups de Recerca AGAUR (2017SGR948); Gilead Fellowship Program GLD14/293; The SPANISH AIDS Research Network [RD16/0002/0001, RD16/0002/0002, RD16/0025/0006, RD16/0025/0013, and RD16/0025/0020]-ISCIII-FEDER (Spain); and the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas-ISCIII [CB21/13/00015, CB21/13/00020, and CB21/13/00044], Madrid, Spain. JM is supported by the Universitat Rovira I Virgili under grant agreement “2019PMF-PIPF-18,” through the call “Martí Franquès Research Fellowship Programme.” NR is a Miguel Servet researcher from the ISCIII [CPII19/00025]. EY is supported by the Instituto de Salud Carlos III (ISCIII) under grant agreement “FI20/0011800” through the program “Contratos Predoctorales de Formación en Investigación en Salud.” ER-M was supported by the Spanish National Research Council (CSIC). FV is supported by grants from the Programa de Intensificación de Investigadores (INT20/00031)-ISCIII and by “Premi a la Trajectòria Investigadora als Hospitals de l’ICS 2018.” AR is supported by IISPV through the project “2019/IISPV/05” (Boosting Young Talent), by GeSIDA through the “III Premio para Jóvenes Investigadores 2019,” and by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CP19/00146” through the Miguel Servet Program. | es_ES |
| dc.format.page | 822272 | es_ES |
| dc.format.volume | 13 | es_ES |
| dc.identifier.citation | Front Immunol. 2022 Apr 20;13:822272. | es_ES |
| dc.identifier.doi | 10.3389/fimmu.2022.822272 | es_ES |
| dc.identifier.e-issn | 1664-3224 | es_ES |
| dc.identifier.journal | Frontiers in Immunology | es_ES |
| dc.identifier.pubmedID | 35514981 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/20.500.12105/14870 | |
| dc.language.iso | eng | es_ES |
| dc.publisher | Frontiers Media | |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0006/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0013/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0020/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD16/0002/0001 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD16/0002/0002 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI13/0796 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI16/00503 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI16/0684 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI18/1532 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI19/00004 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI19/01127 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI19/01337 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI16/001769 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI19/00973 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI20/00326 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CPII19/00025 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/FI20/0011800 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/INT20/00031 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CP19/00146 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CB21/13/00015 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CB21/13/00020 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CB21/13/00044 | es_ES |
| dc.relation.publisherversion | https://doi.org/10.3389/fimmu.2022.822272 | es_ES |
| dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
| dc.repisalud.institucion | ISCIII | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Atribución 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | HIV infection | es_ES |
| dc.subject | Kreb's cycle | es_ES |
| dc.subject | Elite controllers (ECs) | es_ES |
| dc.subject | Lipidomics | es_ES |
| dc.subject | Long-term | es_ES |
| dc.subject | Mass spectrometry | es_ES |
| dc.subject | Metabolomics | es_ES |
| dc.subject | Viral | es_ES |
| dc.subject.mesh | HIV Infections | es_ES |
| dc.subject.mesh | HIV-1 | es_ES |
| dc.subject.mesh | Follow-Up Studies | es_ES |
| dc.subject.mesh | Humans | es_ES |
| dc.subject.mesh | Ketoglutaric Acids | es_ES |
| dc.subject.mesh | Lipids | es_ES |
| dc.title | Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control | es_ES |
| dc.type | research article | es_ES |
| dc.type.hasVersion | VoR | es_ES |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 89b17350-14e3-4dfd-b797-6ee6ca5363b8 | |
| relation.isAuthorOfPublication | 2fc55aca-54b0-411c-b170-c2149068a902 | |
| relation.isAuthorOfPublication.latestForDiscovery | 89b17350-14e3-4dfd-b797-6ee6ca5363b8 | |
| relation.isFunderOfPublication | efa64f05-b985-4984-8f1e-5fc4ef21f502 | |
| relation.isFunderOfPublication | 0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72 | |
| relation.isFunderOfPublication | f236c6af-7ac3-49fe-8a6a-818b321c6130 | |
| relation.isFunderOfPublication | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isFunderOfPublication | 811243fc-9fda-46b1-b312-9259d8c570f6 | |
| relation.isFunderOfPublication | 36ca2ebf-c6c3-4f53-8618-500af224a277 | |
| relation.isFunderOfPublication | af365449-d1bb-4678-af42-7483b561cd83 | |
| relation.isFunderOfPublication | e30731f7-32c2-43af-b658-fe28964bc958 | |
| relation.isFunderOfPublication.latestForDiscovery | efa64f05-b985-4984-8f1e-5fc4ef21f502 | |
| relation.isPublisherOfPublication | 9f9fa5ea-093b-43d8-bf2c-5bd65d08a802 | |
| relation.isPublisherOfPublication.latestForDiscovery | 9f9fa5ea-093b-43d8-bf2c-5bd65d08a802 |
Files
Original bundle
1 - 2 of 2
Loading...
- Name:
- ElevatedαKetoglutaricAcid_2022.pdf
- Size:
- 2.75 MB
- Format:
- Adobe Portable Document Format
- Description:
- Artículo principal
Loading...
- Name:
- ElevatedαKetoglutaricAcidSupplementeryMaterial_2022.pdf
- Size:
- 514.5 KB
- Format:
- Adobe Portable Document Format
- Description:
- Supplementary Information


